Use of nuclear magnetic resonance and near infrared to analyze biological samples

Patent metadata

Field	Value
Publication number	US-9360421-B2
Application number	US-201214241647-A
Country	US
Kind code	B2
Filing date	Aug 31, 2012
Priority date	Sep 1, 2011
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

Abstract

In one aspect, the disclosure provides methods for using NMR and NIR to evaluate biological samples. In some embodiments, the methods include a step of performing a Nuclear Magnetic Resonance (NMR) analysis on a sample to obtain an NMR spectrum, a step of performing a Near Infrared Spectroscopy (NIR) analysis on the sample to obtain an NIR spectrum, and/or a step of performing a data fusion analysis to evaluate the NIR spectrum.

First claim

What is claimed is:

1. A method of identifying one or more informative subsets of frequency ranges of an NIR spectrum for evaluating a biological sample, the method comprising
performing a Nuclear Magnetic Resonance (NMR) analysis on a biological sample to obtain an NMR spectrum,
performing a Near Infrared Spectroscopy (NIR) analysis on the biological sample to obtain an NIR spectrum, and
obtaining one or more informative subsets of NIR frequency ranges of the NIR spectrum by performing a data fusion analysis of the NMR spectrum with the NIR spectrum.

2. The method of claim 1 , wherein the data fusion analysis comprises an Outer Product Analysis (OPA).

3. The method of claim 2 , wherein the OPA comprises multiplying the NMR spectrum with the NIR spectrum.

4. The method of claim 2 , wherein OPA comprises multiplying Regression vectors and Variable Importance in Projection (VIP) vectors.

5. The method of claim 1 , wherein the data fusion analysis comprises a partial least square (PLS) analysis.

6. The method of claim 5 , wherein the PLS analysis comprises an x-block of NIR and NMR data and a y-block of one or more components of the biological sample.

7. The method of claim 5 , wherein the results are displayed using a combination vector.

8. The method of claim 1 , wherein the data fusion analysis is a computer-implemented step.

9. The method of claim 1 further comprising:
performing a second NIR analysis on a second biological sample to obtain a second NIR spectrum, and
evaluating the second biological sample by analyzing the one or more informative subsets of NIR frequency ranges of the second NIR spectrum.

10. The method of claim 1 , wherein the biological sample is a sample of a biological growth or expression system.

11. The method of claim 1 , wherein the biological sample is a starting material for a biological growth or expression system.

12. The method of claim 1 , wherein the biological sample comprises more than three different nutrient components.

13. The method of claim 1 , wherein the biological sample comprises two or more amino acids, peptides, sugars, carbohydrates, vitamins, growth factors, salts, synthetic material, antibiotics, surfactants, buffers, or any combination thereof.

14. The method of claim 1 , wherein the biological sample comprises a surfactant.

15. The method of claim 1 , wherein the biological sample comprises Glutamine (Gln), glucose, and/or phenylalanine (Phe).

16. The method of claim 1 , wherein the biological sample comprises a mixture of nutrients of a biopharmaceutical cell culture media.

17. A method of evaluating a biological sample, the method comprising
performing a Near Infrared Spectroscopy (NIR) analysis on a biological sample to obtain an NIR spectrum for a subset of NIR wavelengths that is informative for evaluating the biological sample,
wherein the subset was identified in a data fusion analysis of a reference NIR spectrum with a reference NMR spectrum.

18. A method of analyzing a biological sample, the method comprising:
performing a Near Infrared Spectroscopy (NIR) analysis on a biological sample to obtain a NIR spectrum, and
evaluating the biological sample by analyzing one or more informative subsets of NIR frequency ranges of the NIR spectrum, wherein the one or more informative subsets of NIR frequency ranges were identified by performing a data fusion analysis of a reference Nuclear Magnetic Resonance (NMR) spectrum with a reference NIR spectrum.

Assignees

• Lanan Maureen
• Ali Amr
• Biogen Ma Inc

Inventors

• Lanan Maureen
• Ali Amr

Classifications

• G01N2201/13

  Standards, constitution · CPC title

• G01R33/465

  applied to biological material, e.g. in vitro testing · CPC title

• G01N2201/12

  Circuits of general importance; Signal processing · CPC title

• G01R33/4808

  Multimodal MR, e.g. MR combined with positron emission tomography [PET], MR combined with ultrasound or MR combined with computed tomography [CT] · CPC title

• G01N33/50

  Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q) · CPC title